Legend Biotech (LEGN) Common Equity (2019 - 2025)

Legend Biotech has reported Common Equity for 7 years, with the latest figure at $1.0 billion in Q1 2025.

• For the quarter ending Q1 2025, Common Equity fell 12.57% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2025 stood at $1.0 billion (down 12.57% YoY), and the FY2024 full-year result was $1.0 billion, down 16.85% from the prior year.
• Common Equity for Q1 2025 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Common Equity was $1.4 billion in Q2 2023, with the low at $206451.0 in Q1 2021.
• Historically, Common Equity has averaged $864.4 million across 5 years, with a median of $1.0 billion in 2025.
• Annual changes were most pronounced in 2022 — Common Equity soared 358900.44% — and 2024, when it dropped 17.63%.
• Legend Biotech's Common Equity stood at $765.9 million in 2021, then dropped by 2.82% to $744.3 million in 2022, then soared by 68.12% to $1.3 billion in 2023, then slipped by 16.85% to $1.0 billion in 2024, then slipped by 2.19% to $1.0 billion in 2025.
• The last three Common Equity figures came in at $1.0 billion (Q1 2025), $1.0 billion (Q4 2024), and $1.1 billion (Q3 2024), per Business Quant data.